Palatin Technologies Inc. (PTN)

[seasonedwell]

Palatin enters supply pact with Catalent in anticipation of FDA approval Palatin (PTN) disclosed in a regulatory filing earlier that, on June 20, it entered into a commercial supply agreement with Catalent Belgium, a subsidiary of Catalent (CTLT) Pharma Solutions. Pursuant to the agreement, Palatin engaged Catalent to manufacture drug product and prefilled syringes, assemble prefilled syringes into an auto-injector device, and package and label the combination product. Palatin intends to engage third parties to provide Catalent with a supply of bremelanotide and the disposable auto-injector device. "Palatin entered into the agreement in anticipation of approval by the FDA of the product. All patients are projected to complete Phase 3 clinical trials of bremelanotide for hypoactive sexual desire disorder by Q3," said Palatin.